Brainstorm Cell Therapeutics (BCLI) Expected to Announce Quarterly Earnings on Monday

Brainstorm Cell Therapeutics (NASDAQ:BCLI) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.28) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 3:00 PM ET.

Brainstorm Cell Therapeutics Stock Down 4.5%

Brainstorm Cell Therapeutics stock opened at $0.84 on Monday. The business’s 50-day simple moving average is $0.64 and its 200 day simple moving average is $0.65. The stock has a market cap of $9.30 million, a price-to-earnings ratio of -0.25 and a beta of 0.69. Brainstorm Cell Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.92.

Brainstorm Cell Therapeutics Company Profile

BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.

The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).